Xeomin® 100u

XEOMIN® 100U powder for solution for injection contains 100 units of incobotulinumtoxin A. Native Botulinum toxin type A is a high molecular weight complex, which, in addition to the toxin (150 kD), contains other bacterial non-toxic proteins, like haemagglutinins and non-haemagglutinins. In contrast to conventional preparations containing the botulinum toxin A complex, Xeomin® contains pure (150 kD) toxin since it is free from complexing proteins and thus has a low foreign protein content. The foreign protein content administered is considered as one of the factors for secondary therapy failure. IncobotulinumtoxinA is produced from the fermentation of Clostridium botulinum and is subsequently purified to remove complexing proteins. It consists of the purified neurotoxin which has been separated from complexing proteins (haemagglutinins and a non-toxic non-haemagglutinating protein) during production. A prescription medicine product used to improve the look of moderate to severe frown lines between the eyebrows. Also to treat abnormal head position, neck pain caused by cervical dystonia. Also improves eyelids that have had prior treatment with anabotulinum toxin type A.

XEOMIN® (incobotulinumtoxinA) is an injectable neuromuscular blocking agent designed for both therapeutic and cosmetic applications. As a purified botulinum toxin product, it works by inhibiting the release of acetylcholine at the neuromuscular junction, leading to temporary muscle relaxation. Xeomin treatment is widely used for conditions such as upper limb spasticity, cervical dystonia, blepharospasm, and the cosmetic reduction of moderate to severe glabellar lines (frown lines).

Patients receiving Xeomin may experience smoother skin and improved muscle function, making it a sought-after anti-wrinkle injection. Its unique formulation, free from accessory proteins, sets it apart from other toxin products like Botox and Dysport, potentially reducing the risk of immunogenicity. Clinically validated since its U.S. approval in 2010, Xeomin injections provide effective relief from muscular contractions, spasticity, and aesthetic concerns, with results typically lasting up to three months.

For those interested in ordering Xeomin, it is available through authorized doctors, licensed healthcare providers, and verified online sources. To ensure safe and effective results, always order Xeomin from trusted sources and consult with a qualified professional before starting treatment.

XEOMIN® 100u Packaging and Ingredients
XEOMIN® 100u is carefully packaged to ensure sterility, accurate dosing, and safe storage. Each vial is clearly labeled with essential product information to help healthcare providers and patients select the right brand when purchasing through an authorized portal or center.

Packaging:
Single-dose vial of 100 units, designed for precision and efficacy.
Type 1 borosilicate glass vials with latex-free bromobutyl rubber closures, reducing trouble with contamination risk.
Proper storage guidelines help maintain product integrity and health safety standards.
Ingredients:
IncobotulinumtoxinA (Botulinum toxin type A): Active neurotoxin for therapeutic and aesthetic treatments.
Human Albumin (1 mg): A stabilizer that supports product effectiveness.
Sucrose (4.7 mg): Another stabilizer ensuring consistent results.
Before starting treatment, patients should verify their savings program eligibility and check insurance coverage, price variations, and supplier credibility. Those who have received XEOMIN® should adhere to storage and handling instructions. Additionally, pediatric patients and their caregivers should consult a doctor for guidance. When browsing online, review cookie policies to ensure secure transactions.

CONTRAINDICATIONS

Known hypersensitivity to any botulinum toxin product or to any of the components (human albumin, sucrose) in the formulation.
Infection at the proposed injection site(s) because it could lead to severe local or disseminated infection.

WARNINGS AND PRECAUTIONS

The potency units of XEOMIN are specific to the preparation and assay method utilized. Units of biological activity of Xeomin cannot be compared to or converted into Units of any other botulinum toxin products assessed with any other specific assay method.
Serious hypersensitivity reactions (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea) have been reported with botulinum toxin products. If serious and/or immediate hypersensitivity reactions occur, discontinue further injection of XEOMIN and institute appropriate medical therapy immediately.
Treatment with XEOMIN and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. When distant effects occur, additional respiratory muscles may be involved. Patients may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. Dysphagia may persist for several months, which may require use of a feeding tube. Aspiration may result from severe dysphagia.
Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) may be at increased risk for severe dysphagia and respiratory compromise from typical doses of XEOMIN.
Cervical Dystonia: Treatment with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation. This may result in critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles. There have been post- marketing reports of serious breathing difficulties, including respiratory failure, in patients with cervical dystonia treated with botulinum toxin products. Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscles are at greater risk of dysphagia. Limiting the dose injected into the sternocleidomastoid muscle may decrease the occurrence of dysphagia.
Blepharospasm: Reduced blinking from injection of botulinum toxin products into the orbicularis muscle can lead to corneal exposure, persistent epithelial defect, and corneal ulceration, especially in patients with VII nerve disorders. Patients with previous eye surgery should be carefully assessed for corneal sensation before treatment. Xeomin should be used with caution in patients at risk of developing narrow angle glaucoma. To decrease the risk for ectropion, XEOMIN should not be injected into the medial lower eyelid area.
XEOMIN contains human serum albumin. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD). No cases of transmission of viral diseases, CJD, or vCJD have ever been reported for licensed albumin or albumin contained in other licensed products.
Use caution when XEOMIN is used where the targeted muscle shows excessive weakness or atrophy.
Use caution when XEOMIN is used in patients who have marked facial asymmetry, with surgical alterations to the facial anatomy, pre-existing eyelid or eyebrow ptosis, when excessive weakness or atrophy is present in the target muscles, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin (e.g., the inability to substantially lessen glabellar lines even by physically spreading them apart).

ADVERSE REACTIONS
The most commonly observed adverse reactions at rates specified below and greater than placebo are:

Chronic Sialorrhea:
in adults (≥4% of patients): tooth extraction, dry mouth, diarrhea, and hypertension.
in pediatric patients (≥1% of patients): bronchitis, headache, and nausea/vomiting.
Upper Limb Spasticity
in adults (≥2% of patients): seizure, nasopharyngitis, dry mouth, and upper respiratory tract infection.
in pediatric patients (≥3% of patients): nasopharyngitis and bronchitis.
Cervical Dystonia in adults (≥5% of patients): dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain.
Blepharospasm in adults (≥10% of patients): eyelid ptosis, dry eye, visual impairment, and dry mouth